H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $49
Analysts' Top Healthcare Picks: TG Therapeutics (TGTX), Boston Scientific (BSX)
TG Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $49 Price Target
Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $20
Goldman Sachs Maintains TG Therapeutics(TGTX.US) With Hold Rating, Raises Target Price to $20
Maintaining Hold on TG Therapeutics Amidst Positive Performance and Ongoing Uncertainties
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $49 Price Target
TG Therapeutics Analyst Ratings
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $34
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $49
Bullish on Briumvi: Buy Rating Affirmed for TG Therapeutics Amid Strong Financials and Market Adoption
HC Wainwright & Co. : TG Therapeutics (TGTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $45.00 to $49.00.
TG Therapeutics Analyst Ratings
Ladenburg Thalmann Maintains Buy on TG Therapeutics, Raises Price Target to $40
Sell Rating on TG Therapeutics: Caution Amid Competitive Threats and Decelerating Prescription Growth
Hold Rating on TG Therapeutics Amidst Strong Briumvi Launch and Competitive Market Pressures
Briumvi's Market Share Growth and TG Therapeutics' Strong Financial Outlook Justify Buy Rating
Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)
Komo: The TG Therapeutics (TGTX.US) rating was confirmed and adjusted from an increase in holdings to an increase in holdings rating, with a target price of $25.00.